10.02.20
8 min. Read

Proteus founders explain. Investors talk DTx.

Issue 072.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I published The Virgin Pulse Report. Thanks to everyone who sent in feedback. Here's what's happening this week:

  • I am working my way through some long write-ups of the DTx East event, which took place virtually in September. The first of a few quasi-transcripts of discussions at the event

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
NightWare revenue. Oui terminates trial. 2025 FDA guidance priorities, posteriorities
1.17.25
7 min. Read
NY Medicaid won’t pay for Freespira, CanvasDx. Insolvent Mahana’s first asset sale.
12.13.24
9 min. Read
Final Fee Schedule: How CMS tweaked its digital mental health treatment G-codes
11.01.24
5 min. Read
CMS prices MedRhythms InTandem. Big Health courts health systems
10.11.24
4 min. Read
Mahana Therapeutics’ insolvency. FDA clears Happy Ring (Tinder founder’s smart ring)
10.04.24
6 min. Read
Flashback: How Proteus Digital Health’s outcomes-based pricing worked for Tennessee Medicaid
9.20.24
5 min. Read
Are the Digital Mental Health Treatment G Codes necessary? Or RTM dupes?
7.12.24
7 min. Read
Which PDTs are still around? New bill in Congress.
6.28.24
10 min. Read
FDA OKs Alivecor (12L?), Akili OTC. Oui eyes obesity.
6.21.24
5 min. Read
Digging into the Akili-Virtual Therapeutics deal
5.31.24
10 min. Read
  • First
  • Previous
  • 1 of 22
  • Next
  • Last